ARMATA PHARMACEUTICALS, INC. Derivative Liability, Fair Value, Gross Liability
ARMATA PHARMACEUTICALS, INC. (ARMP) had Derivative Liability, Fair Value, Gross Liability of $0 as of 2020-12-31, per its 10-K filed 2021-03-18.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2021-03-18
- 2020-12-31: Derivative Liability, Fair Value, Gross Liability $0.00.
- 2020-09-30: Derivative Liability, Fair Value, Gross Liability $0.00.
- 2020-06-30: Derivative Liability, Fair Value, Gross Liability $0.00.
- 2020-03-31: Derivative Liability, Fair Value, Gross Liability $0.00.
| Period end | Derivative Liability, Fair Value, Gross Liability | Derivative Liability, Fair Value, Gross Liability as first filed |
|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-18 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-13 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-14 | |
| 2019-05-09 | $2.90M 10-K · filed 2020-03-19 | |
| 2019-03-31 | $33.00K 10-Q · filed 2019-05-06 | |
| 2018-12-31 | $1.10M 10-K · filed 2021-03-18 | $22.00K 10-Q · filed 2019-05-06 |
| 2018-09-30 | $154.00K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $185.00K 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $187.00K 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $292.00K 10-Q · filed 2018-11-08 | |
| 2017-09-30 | $400.00K 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $387.00K 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $2.33M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $2.44M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $1.65M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $1.47M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $93.00K 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $1.50M 10-K · filed 2017-03-27 | |
| 2015-09-30 | $2.14M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | $14.02M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $34.15M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $18.15M 10-K · filed 2016-03-30 | |
| 2013-12-31 | $57.66M 10-K · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |